No profile data available.
Madrigal Pharmaceuticals, Inc. (MDGL) is a healthcare company in the hepatic treatment pharmaceuticals industry, based in West Conshohocken, United States, with about 915 full-time employees.
It reported revenue of $958.40 million for fiscal year 2025, up 432.1% from fiscal year 2024, and net income of -$288.28 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $364.25 million, up 71.2% from a year before. Its market capitalization was $10.90 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals reported $958.40 million in revenue for fiscal year 2025, up 432.1% from $180.13 million in fiscal year 2024. In Q2 2026 revenue was $364.25 million.
$10.90 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (hepatic treatment pharmaceuticals) include Arrowhead Pharmaceuticals, Inc. (ARWR), Mirum Pharmaceuticals, Inc. (MIRM), Inventiva S.a. (IVA), Wave Life Sciences Ltd. (WVE).